Clinical Trial Phases

Overview

The clinical trial system is the structured process through which experimental therapies — including peptides — are evaluated for safety and efficacy in humans. Overseen by regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), this multi-phase process typically spans 10 to 15 years and costs hundreds of millions to billions of dollars.

Understanding clinical trial phases is essential for interpreting the development status of any peptide. When a peptide is described as being "in Phase II trials," this carries specific meaning about what is known and, critically, what remains unknown about that compound.

Preclinical Stage

Before any human testing begins, a compound must demonstrate safety and biological activity in laboratory and animal studies. The preclinical phase includes:

• In vitro studies — Cell-based experiments to characterize mechanism, potency, and selectivity
• In vivo animal studies — Safety, pharmacokinetics, and preliminary efficacy in rodent and non-rodent species
• Toxicology studies — Acute and chronic toxicity assessment, including maximum tolerated dose
• Manufacturing and formulation — Development of a consistent, reproducible manufacturing process
• Investigational New Drug (IND) application — Formal submission to the FDA requesting permission to begin human trials

Preclinical development typically takes 3 to 6 years. The vast majority of research peptides exist only at this stage, with no human data available.

Phase I — Safety and Pharmacokinetics

Purpose

The primary objective of Phase I is to establish basic safety, tolerability, and pharmacokinetic profile in humans. Efficacy is not a primary endpoint.

Design

• Participants: 20 to 100 healthy volunteers (or patients with the target disease if the compound is too toxic for healthy individuals, such as oncology therapies)
• Duration: Several months
• Key measures: Maximum tolerated dose, dose-limiting toxicities, absorption, distribution, metabolism, excretion (ADME profile)
• Design types: Single ascending dose (SAD), multiple ascending dose (MAD), food-effect studies

What Phase I Tells Us

• The compound is safe enough for further testing at specific dose ranges
• How the body processes the compound (pharmacokinetics)
• What side effects occur at various doses
• The appropriate dose range for Phase II

What Phase I Does Not Tell Us

• Whether the compound is effective for any condition
• Long-term safety
• How it compares to existing treatments

Approximately 70% of compounds pass Phase I.

Phase II — Preliminary Efficacy

Purpose

Phase II evaluates whether the compound produces the intended therapeutic effect and refines dosing. It is divided into two sub-phases:

• Phase IIa — Proof of concept. Does the compound show biological activity at the proposed mechanism?
• Phase IIb — Dose-finding. What dose or dose range produces the optimal balance of efficacy and safety?

Design

• Participants: 100 to 300 patients with the target condition
• Duration: Several months to 2 years
• Key measures: Efficacy endpoints (which vary by disease), dose-response relationship, continued safety monitoring
• Design types: Typically randomized, double-blind, placebo-controlled

What Phase II Tells Us

• Whether the compound shows preliminary efficacy in the target population
• The optimal dose range for further testing
• Common adverse effects in patients (not just healthy volunteers)

What Phase II Does Not Tell Us

• Whether efficacy is durable or clinically meaningful at larger scale
• Rare side effects (sample too small)
• How it compares to existing standard-of-care treatments (unless active comparator is included)

Approximately 33% of compounds pass Phase II — this is the stage with the highest failure rate.

Phase III — Confirmatory Efficacy

Purpose

Phase III trials are large-scale studies designed to confirm efficacy, monitor side effects, compare against existing treatments, and generate the data required for regulatory approval.

Design

• Participants: 300 to 3,000+ patients (sometimes tens of thousands)
• Duration: 1 to 4 years
• Key measures: Primary efficacy endpoints, safety profile, quality-of-life measures, comparison to standard of care
• Design types: Randomized, double-blind, placebo-controlled and/or active comparator; often multi-center and international

What Phase III Tells Us

• Whether the compound is effective in a large, diverse patient population
• The full spectrum of common and moderately rare adverse effects
• How it compares to existing treatments
• The benefit-risk ratio that regulators will evaluate

Regulatory Submission

Successful Phase III results lead to a New Drug Application (NDA) or Biologics License Application (BLA) submitted to the FDA. The review process typically takes 6 to 12 months, though priority review and breakthrough therapy designations can accelerate this timeline.

Approximately 25-30% of compounds that enter Phase III ultimately receive FDA approval.

Phase IV — Post-Market Surveillance

Purpose

Phase IV studies occur after a drug has been approved and marketed. They serve to:

• Monitor long-term safety in real-world populations
• Identify rare adverse effects not detected in smaller trials
• Explore additional indications
• Study drug interactions and use in special populations (elderly, pediatric, pregnant)
• Fulfill post-marketing commitments required by regulators

Design

• Participants: Thousands to millions (through registries, observational studies, and electronic health records)
• Duration: Ongoing, often spanning years to decades
• Key measures: Rare adverse events, long-term outcomes, real-world effectiveness

Peptides in the Clinical Trial Pipeline

Approved Peptide Drugs

Several peptides have completed the full regulatory pathway:

• Semaglutide (Ozempic, Wegovy) — GLP-1 receptor agonist approved for type 2 diabetes and obesity
• Tirzepatide (Mounjaro, Zepbound) — Dual GIP/GLP-1 agonist approved for diabetes and weight management
• Bremelanotide — Melanocortin receptor agonist approved for hypoactive sexual desire disorder

Peptides in Active Trials

Numerous peptides are currently in various phases of clinical development, including next-generation GLP-1 agonists, antimicrobial peptides, and peptide-drug conjugates for oncology.

Research Peptides Without Clinical Data

The majority of peptides discussed in the research community — including BPC-157, TB-500, Dihexa, and many others — have not entered formal clinical trials or have only limited early-phase data. Claims of efficacy for these compounds rest primarily on animal model data and should be interpreted accordingly.

Special Regulatory Pathways

Several mechanisms exist to accelerate development for compounds addressing serious conditions:

• Fast Track — More frequent meetings with FDA, eligibility for rolling review
• Breakthrough Therapy — Intensive FDA guidance, expedited review for compounds showing substantial improvement over existing treatments
• Accelerated Approval — Based on surrogate endpoints reasonably likely to predict clinical benefit; post-marketing studies required to confirm benefit
• Priority Review — FDA action within 6 months rather than the standard 10 months

Understanding What Trial Phase Means

When evaluating any peptide, the clinical trial status provides critical context:

Status	What It Means
Preclinical only	Animal/cell data only; no proven human safety or efficacy
Phase I completed	Basic safety established at specific doses; no efficacy data
Phase II ongoing	Preliminary efficacy being evaluated; results not yet confirmed
Phase III completed	Efficacy confirmed in large trials; likely nearing approval
FDA approved	Full regulatory review completed; benefit-risk deemed acceptable

This framework helps calibrate expectations and prevents the common error of treating early-stage or preclinical findings as established medical facts.